Why your second COVID-19 vaccine dose really matters

Doses of Pfizer/BioNTech coronavirus disease (COVID-19) vaccine are seen in a try as the Chilean sanitary authority starts a vaccination campaign for people from 12 to 17 years old in Santiago, Chile June 23, 2021. REUTERS/Ivan Alvarado - RC2G6O9UIXGG

The second dose has 'powerful beneficial effects.' Image: REUTERS/Ivan Alvarado

Bruce Goldman
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


  • New research published in nature explores the immune response following the Pfizer/BioNTech COVID-19 vaccine.
  • The research suggests the second dose has 'beneficial effects that far exceed those of the first shot'.
  • The Pfizer BioNTech and Moderna COVID-19 vaccines work differently from traditional vaccines so researchers wanted to know more about the immune system response.

The second shot of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study.

The finding strongly supports the view that the second shot should not be skipped.

“Despite their outstanding efficacy, little is known about how exactly RNA vaccines work,” says Bali Pulendran, professor of pathology and of microbiology and immunology at Stanford University. “So we probed the immune response induced by one of them in exquisite detail.”

The study, which appears in Nature, was designed to find out exactly what effects the vaccine, marketed by Pfizer Inc., has on the numerous components of the immune response.

The researchers analyzed blood samples from individuals inoculated with the vaccine. They counted antibodies, measured levels of immune-signaling proteins and characterized the expression of every single gene in the genome of 242,479 separate immune cells’ type and status.

Have you read?

The second shot and your immune system

“The world’s attention has recently been fixed on COVID-19 vaccines, particularly on the new RNA vaccines,” says Pulendran.

“This is the first time RNA vaccines have ever been given to humans, and we have no clue as to how they do what they do: offer 95% protection against COVID-19,” says Pulendran.

Traditionally, the chief immunological basis for approval of new vaccines has been their ability to induce neutralizing antibodies: individualized proteins, created by immune cells called B cells, that can tack themselves to a virus and block it from infecting cells.

“Antibodies are easy to measure,” Pulendran says. “But the immune system is much more complicated than that. Antibodies alone don’t come close to fully reflecting its complexity and potential range of protection.”

Pulendran and his colleagues assessed goings-on among all the immune cell types influenced by the vaccine: their numbers, their activation levels, the genes they express, and the proteins and metabolites they manufacture and secrete upon inoculation.

One key immune-system component the researchers examined was T cells: search-and-destroy immune cells that don’t attach themselves to viral particles as antibodies do but rather probe the body’s tissues for cells bearing telltale signs of viral infections. On finding them, they tear those cells up.

COVID-19 vaccine doses administered globally
COVID-19 vaccine doses administered globally. Image: Our World in Data

In addition, the innate immune system, an assortment of first-responder cells, is now understood to be of immense importance. It’s the body’s sixth sense, Pulendran says, whose constituent cells are the first to become aware of a pathogen’s presence. Although they’re not good at distinguishing among separate pathogens, they secrete “starting gun” signaling proteins that launch the response of the adaptive immune system—the B and T cells that attack specific viral or bacterial species or strains.

During the week or so it takes for the adaptive immune system to rev up, innate immune cells perform the mission-critical task of holding incipient infections at bay by gobbling up—or firing noxious substances, albeit somewhat indiscriminately, at—whatever looks like a pathogen to them.

The Pfizer vaccine, like the one made by Moderna Inc., works quite differently from the classic vaccines composed of live or dead pathogens, individual proteins, or carbohydrates that train the immune system to zero in on a particular microbe and wipe it out. The Pfizer and Moderna vaccines instead contain genetic recipes for manufacturing the spike protein that SARS-CoV-2, the virus that causes COVID-19, uses to latch on to cells it infects.


'Powerful, beneficial effects'

In December 2020, Stanford Medicine began inoculating people with the Pfizer vaccine. This spurred Pulendran’s desire to assemble a complete report card on the immune response to it.

The team selected 56 healthy volunteers and drew blood samples from them at multiple time points preceding and following the first and second shots. The researchers found that the first shot increases SARS-CoV-2-specific antibody levels, as expected, but not nearly as much as the second shot does. The second shot also does things the first shot doesn’t do, or barely does.

“The second shot has powerful beneficial effects that far exceed those of the first shot,” Pulendran says. “It stimulated a manifold increase in antibody levels, a terrific T-cell response that was absent after the first shot alone, and a strikingly enhanced innate immune response.”

Unexpectedly, Pulendran says, the vaccine—particularly the second dose—caused the massive mobilization of a newly discovered group of first-responder cells that are normally scarce and quiescent.

First identified in a recent vaccine study led by Pulendran, these cells—a small subset of generally abundant cells called monocytes that express high levels of antiviral genes—barely budge in response to an actual COVID-19 infection. But the Pfizer vaccine induced them.

This special group of monocytes, which are part of the innate museum, constituted only 0.01% of all circulating blood cells prior to vaccination. But after the second Pfizer-vaccine shot, their numbers expanded 100-fold to account for a full 1% of all blood cells. In addition, their disposition became less inflammatory but more intensely antiviral. They seem uniquely capable of providing broad protection against diverse viral infections, Pulendran says.

“The extraordinary increase in the frequency of these cells, just a day following booster immunization, is surprising,” Pulendran says. “It’s possible that these cells may be able to mount a holding action against not only SARS-CoV-2 but against other viruses as well.”

Additional coauthors are from Stanford and the Yerkes National Primate Research Center in Atlanta. Researchers at Billerica, Massachusetts-based Quanterix, and Emory University also contributed to the study.

Funding for the work came from the National Institutes of Health, Open Philanthropy, the Sean Parker Cancer Institute, the Soffer Endowment, the Violetta Horton Endowment, Stanford University, the Henry Gustav Floren Trust, the Parker Foundation, the Cooperative Centers on Human Immunology, and the Crown Foundation.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global Health
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum